# A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

> **NCT06626919** · PHASE1 · RECRUITING · sponsor: **Arcellx, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Muscular Diseases
- Neuromuscular Manifestations
- Autoimmune
- Autoimmune Diseases
- Autoimmune Diseases of the Nervous System
- Myasthenia Gravis
- Muscle Weakness

## Interventions

- **BIOLOGICAL:** anito-cel
- **DRUG:** Standard Lymphodepletion regimen

## Key facts

- **NCT ID:** NCT06626919
- **Lead sponsor:** Arcellx, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-30
- **Primary completion:** 2027-03
- **Final completion:** 2028-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06626919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06626919, "A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06626919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*